Type Whole antibody Target IGF-1R CAS Number 1036734-93-6 | Source Human ATC code none ChemSpider none | |
Teprotumumab (RG-1507) is an experimental human monoclonal antibody developed by Genmab and Roche. It binds to IGF-1R.
Teprotumumab was first investigated for the treatment of solid and hematologic tumors, including breast cancer, Hodgkin's and non-Hodgkin's lymphoma, non-small cell lung cancer and sarcoma. Although results of phase I and early phase II trials showed promise, research for these indications were discontinued in 2009 by Roche. Phase II trials still in progress were allowed to complete, as the development was halted due to business prioritization rather than safety concerns.
Teprotumumab was subsequently licensed to River Vision Development Corporation in 2012 for research in the treatment of ophthalmic conditions. It is in phase II trials for Graves' ophthalmopathy and phase I for diabetic macular edema. It was granted Orphan Drug Status by the FDA for Graves' ophthalmopathy.